Hoth Therapeutics Files 8-K

Ticker: HOTH · Form: 8-K · Filed: 2024-11-08T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-statements

TL;DR

Hoth Therapeutics filed an 8-K on Nov 8, 2024 - material agreement and financials filed.

AI Summary

Hoth Therapeutics, Inc. filed an 8-K on November 8, 2024, to report the entry into a material definitive agreement and to file financial statements and exhibits. The filing does not contain specific details about the agreement or financial figures within the provided text.

Why It Matters

This filing indicates a significant event or update for Hoth Therapeutics, Inc., potentially impacting investors and stakeholders.

Risk Assessment

Risk Level: low — The filing is a standard corporate disclosure and does not inherently present new risks without further details on the material agreement.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Hoth Therapeutics, Inc.?

The provided text of the 8-K filing does not specify the details of the material definitive agreement.

When was the 8-K filing submitted by Hoth Therapeutics, Inc.?

The 8-K filing was submitted on November 8, 2024.

What is the state of incorporation for Hoth Therapeutics, Inc.?

Hoth Therapeutics, Inc. is incorporated in Nevada.

What is the principal executive office address for Hoth Therapeutics, Inc.?

The principal executive office address is 590 Madison Ave., 21st Floor, New York, New York 10022.

What are the two main items reported in this 8-K filing?

The filing reports the entry into a material definitive agreement and the filing of financial statements and exhibits.

From the Filing

0001213900-24-096007.txt : 20241108 0001213900-24-096007.hdr.sgml : 20241108 20241108173035 ACCESSION NUMBER: 0001213900-24-096007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241108 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241108 DATE AS OF CHANGE: 20241108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 241441996 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 ea0220438-8k_hoth.htm CURRENT REPORT false 0001711786 NY 0001711786 2024-11-08 2024-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported)  November 8, 2024   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   590 Madison Ave ., 21 st Floor New York ,  New York   10022 (Address of principal executive offices, including ZIP code)   ( 646 )  756-2997 (Registrant’s telephone number, including area code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The  Nasdaq  Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐           Item 1.01 Entry into a Material Definitive Agreement.   On November 8, 2024, Hoth Therapeutics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), under which the Company may offer and sell shares of its common stock, par value $0.0001 per share, (the “Shares”), having an aggrega

View on Read The Filing